CareLit Fachartikel
The multikinase-inhibitor Sorafenib prevents neoangiogenesis and higher NO production by the hepatic artery in CCl4-induced liver cirrhosis
A Zipprich, B Christ, T Seufferlein, M Dollinger · Zeitschrift für Gastroenterologie · 2010 · Heft 01
Dokument
1107104
CareLit-ID
Jahr
2010
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
The vascular resistance and the response of the hepatic artery (HA) to vasoconstrictors is decreased in cirrhosis due to neoangiogenesis, remodeling, and increased NO production (JHEP 2008;49: 739). Sorafenib is a multikinase-inhibitor that decreases neoangiogenesis. The aim of the study was to investigate the hemodynamic effect of the administration of Sorafenib during the development of cirrhosis on the HA. Methods: Cirrhosis was induced by CCl4-inhalation in presence (n=10) or absence (n=11) of Sorafenib (5mg/kg b.w. per day). Bivascular liver perfusion with measurement of the sinusoidal resistance was perfor…
Schlagworte
Cirrhotic
Sorafenib-Treated
Sorafenib
Hepatic
Cirrhosis
Artery
Resistance
Response
Normal
Animals
Neoangiogenesis
Vascular
Zeitschrift für Gastroenterologie
